2021
DOI: 10.1001/jamainternmed.2020.6820
|View full text |Cite|
|
Sign up to set email alerts
|

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

Abstract: ; for the CORIMUNO-19 Collaborative Group IMPORTANCE Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19). OBJECTIVE To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia. DESIGN, SETTING, AND PARTICPANTS This cohort-embedded, investigator-initiated, multicenter, open-label, bayesian randomized clinical trial investigating patients with COVID-19 and moderate or se… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

20
842
5
29

Year Published

2021
2021
2021
2021

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 730 publications
(914 citation statements)
references
References 21 publications
20
842
5
29
Order By: Relevance
“…39 These studies have also demonstrated significant heterogeneity in cytokine expression, underscoring the importance of timely measurement for prognostication, and eventually stratification in clinical trials. Anti-IL6 therapy in COVID-19 is under investigation in multiple clinical trials [42][43][44] and has been employed in clinical practice as an off-label use. Results from trials of the anti-IL-6 receptor tocilizumab have not demonstrated efficacy in preventing intubation or death in moderately ill hospitalized patients with COVID-19.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…39 These studies have also demonstrated significant heterogeneity in cytokine expression, underscoring the importance of timely measurement for prognostication, and eventually stratification in clinical trials. Anti-IL6 therapy in COVID-19 is under investigation in multiple clinical trials [42][43][44] and has been employed in clinical practice as an off-label use. Results from trials of the anti-IL-6 receptor tocilizumab have not demonstrated efficacy in preventing intubation or death in moderately ill hospitalized patients with COVID-19.…”
Section: Resultsmentioning
confidence: 99%
“…Results from trials of the anti-IL-6 receptor tocilizumab have not demonstrated efficacy in preventing intubation or death in moderately ill hospitalized patients with COVID-19. 42,43 However, in a retrospective study of critically ill patients with COVID-19, early treatment with tocilizumab was associated with reduced mortality. 44 These results confirm that rapid, reliable, and repeatable direct cytokine measurement is needed to facilitate precision administration of anti-cytokine therapies only in patients who are experiencing severe cytokine storm.…”
Section: Resultsmentioning
confidence: 99%
“…Tocilizumab may have had a positive impact on COVID-19 outcome in the Italian cohort and appears as a potential therapeutic option. 7 Glucocorticoids (such as dexamethasone at a dose of 6 mg once per day during 10 days) could also modulate inflammation-mediated lung injury caused by Sars-Cov-2 and may reduce 28-day mortality among pneumonia requiring invasive mechanical ventilation or oxygen. 8 Future studies will need to clarify the impact of tocilizumab and glucocorticoids on COVID-19 outcome in patients with LVV.…”
Section: Correspondencementioning
confidence: 99%
“…Previously approved for the treatment of severe or life-threatening chimeric antigen receptor (CAR) T cellinduced CRS, its ability to downregulate the immune system may provide bene cial effects against COVID-19 [7,8]. Studies have demonstrated tocilizumab to be associated with improvements in in ammatory markers, clinical response, and survival [9][10][11][12][13][14][15][16][17][18][19][20][21]. During an unprecedented time when proven effective therapies are lacking, we aimed to describe our real-life experience using tocilizumab for COVID-19.…”
Section: Introductionmentioning
confidence: 99%